FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2073888767> ?p ?o ?g. }

• W2073888767 abstract "The incidence of thyroid cancer has grown over the last three decades, and in the United States, it has increased more than any other cancer (1, 2). Differentiated thyroid cancer (DTC) is the most common of all thyroid cancers, accounting for approximately 90% of cases, and includes papillary, follicular, and hurthle cell histologies (3). Although most patients with DTC have a favorable prognosis with standard treatments, including surgery, radioactive iodine (RAI), and TSH suppression, 10–15% of patients will develop disease refractory to RAI therapy (4, 5). These patients have a median overall survival of 2.5 to 3.5 years (6, 7). For decades, standard therapy for RAI-refractory DTC consisted of cytotoxic chemotherapy with doxorubicin, with unsatisfactory results and side effects (8). The discovery of oncogenic v-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in papillary thyroid cancer in 2003 and the recognition that thyroid cancers are also highly vascular paved the way for the use of sorafenib in metastatic RAI-refractory DTC. A serine-threonine kinase inhibitor, sorafenib, has been found to have multiple targets including VEGFR1–3, platelet derived growth factor receptor beta (PDGFR ), V-Raf-1 murine Leukemia viral oncogene homolog (RAF-1), and BRAF (9). Its activity in DTC, first shown in phase II studies, resulted in the design and execution of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic RAI-refractory DTC (10–12). DECISION was important in helping to define patients with RAI-refractory DTC that were in need of systemic therapy in addition to determining the benefit of sorafenib. Patients were eligible if they met criteria for RAI-refractory disease, defined either as: 1) Having received a total lifetime dose of greater than or equal to 600mCi, 2) The presence of progressing lesions that were RAI non-Avid, or 3) The presence of lesions that had progressed in the period immediately after a therapeutic dose of RAI (12). Furthermore, patients needed to have met RECIST (Response Evaluation Criteria In Solid Tumors) criteria for progressive disease in the year before going on study, which included progression of target lesions by 20% or the development of new lesions (12). The study met its primary endpoint; the median progression free survival (PFS) in the sorafenib arm was 10.8 months, compared to 5.8 months in the placebo arm (hazard ratio, 0.587; P .0001) (12). In November of 2013, based on the data from DECISION, sorafenib became the first multikinase inhibitor (MKI) to be approved by the Food and Drug Administration for the treatment of RAI-refractory progressive DTC. This was practice changing; patients now had a tolerable systemic therapy to manage progressive, RAI-refractory disease. However, the median PFS for patients who receive sorafenib in the first-line setting is 10.8 months (12), leaving open the question of which therapies to consider in the second-line setting. This is especially important because most patients who stop treatment because of disease progression or the development of intolerable or unmanageable adverse events often maintain a good performance status and are candidates for subsequent therapy. In this issue of the JCEM, Dadu et al (13) report results of their retrospective analysis examining the efficacy of second-line therapy in patients with metastatic, RAI-refractory DTC previously treated with sorafenib." @default.
• W2073888767 created "2016-06-24" @default.
• W2073888767 creator A5009392187 @default.
• W2073888767 creator A5025890076 @default.
• W2073888767 date "2014-06-01" @default.
• W2073888767 modified "2023-09-23" @default.
• W2073888767 title "Second-Line Treatment for Advanced Thyroid Cancer: An Indication in Need of Randomized Clinical Trials" @default.
• W2073888767 cites W1846127375 @default.
• W2073888767 cites W1940998999 @default.
• W2073888767 cites W1984185945 @default.
• W2073888767 cites W2025066188 @default.
• W2073888767 cites W2027242209 @default.
• W2073888767 cites W2040268038 @default.
• W2073888767 cites W2040642592 @default.
• W2073888767 cites W2055249187 @default.
• W2073888767 cites W2079186201 @default.
• W2073888767 cites W2087614255 @default.
• W2073888767 cites W2089971534 @default.
• W2073888767 cites W2112129582 @default.
• W2073888767 cites W2114369763 @default.
• W2073888767 cites W2118604864 @default.
• W2073888767 cites W2118868641 @default.
• W2073888767 cites W2130134089 @default.
• W2073888767 cites W2131978083 @default.
• W2073888767 cites W2133354058 @default.
• W2073888767 cites W2140765540 @default.
• W2073888767 cites W2146306052 @default.
• W2073888767 cites W2155008672 @default.
• W2073888767 cites W2158801409 @default.
• W2073888767 doi "https://doi.org/10.1210/jc.2014-2236" @default.
• W2073888767 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24893137" @default.
• W2073888767 hasPublicationYear "2014" @default.
• W2073888767 type Work @default.
• W2073888767 sameAs 2073888767 @default.
• W2073888767 citedByCount "2" @default.
• W2073888767 countsByYear W20738887672014 @default.
• W2073888767 countsByYear W20738887672017 @default.
• W2073888767 crossrefType "journal-article" @default.
• W2073888767 hasAuthorship W2073888767A5009392187 @default.
• W2073888767 hasAuthorship W2073888767A5025890076 @default.
• W2073888767 hasBestOaLocation W20738887671 @default.
• W2073888767 hasConcept C121608353 @default.
• W2073888767 hasConcept C126322002 @default.
• W2073888767 hasConcept C143998085 @default.
• W2073888767 hasConcept C2778019345 @default.
• W2073888767 hasConcept C2778695046 @default.
• W2073888767 hasConcept C2779341817 @default.
• W2073888767 hasConcept C2779761222 @default.
• W2073888767 hasConcept C2781461381 @default.
• W2073888767 hasConcept C502942594 @default.
• W2073888767 hasConcept C526584372 @default.
• W2073888767 hasConcept C71924100 @default.
• W2073888767 hasConceptScore W2073888767C121608353 @default.
• W2073888767 hasConceptScore W2073888767C126322002 @default.
• W2073888767 hasConceptScore W2073888767C143998085 @default.
• W2073888767 hasConceptScore W2073888767C2778019345 @default.
• W2073888767 hasConceptScore W2073888767C2778695046 @default.
• W2073888767 hasConceptScore W2073888767C2779341817 @default.
• W2073888767 hasConceptScore W2073888767C2779761222 @default.
• W2073888767 hasConceptScore W2073888767C2781461381 @default.
• W2073888767 hasConceptScore W2073888767C502942594 @default.
• W2073888767 hasConceptScore W2073888767C526584372 @default.
• W2073888767 hasConceptScore W2073888767C71924100 @default.
• W2073888767 hasLocation W20738887671 @default.
• W2073888767 hasLocation W20738887672 @default.
• W2073888767 hasOpenAccess W2073888767 @default.
• W2073888767 hasPrimaryLocation W20738887671 @default.
• W2073888767 hasRelatedWork W1966504330 @default.
• W2073888767 hasRelatedWork W1974041167 @default.
• W2073888767 hasRelatedWork W1979139803 @default.
• W2073888767 hasRelatedWork W2030889776 @default.
• W2073888767 hasRelatedWork W2037631372 @default.
• W2073888767 hasRelatedWork W2040058909 @default.
• W2073888767 hasRelatedWork W2051784208 @default.
• W2073888767 hasRelatedWork W2064362993 @default.
• W2073888767 hasRelatedWork W2132898409 @default.
• W2073888767 hasRelatedWork W2391409986 @default.
• W2073888767 isParatext "false" @default.
• W2073888767 isRetracted "false" @default.
• W2073888767 magId "2073888767" @default.
• W2073888767 workType "article" @default.